Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System

There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were h...

Descripción completa

Detalles Bibliográficos
Autores principales: Dryden-Peterson, Scott, Kim, Andy, Joyce, Mary-Ruth, Johnson, Jennifer A, Kim, Arthur Y, Baden, Lindsey R, Woolley, Ann E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620388/
https://www.ncbi.nlm.nih.gov/pubmed/36438619
http://dx.doi.org/10.1093/ofid/ofac565
Descripción
Sumario:There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).

Ejemplares similares